Isolation of bioactive proteins from natural product extracts

我们的努力也导致了几类生物活性蛋白质的发现 作为其潜在活动的出版物。这项研究也导致了34项专利 不同的被许可人对我们的发现都很感兴趣。近期论文 特别令人感兴趣的包括我们的报告的快速溶解制剂的蛋白质 griffithsin（GRFT），其显示出针对SHIV、HSV-2和HPV的体内活性，18 GRFT与其他两种候选杀微生物剂17的研究结果导致了新的专利申请， 一类新的称为Tyr-锁肽的环肽的发现也导致了 新专利。PCMBS项目2成功的另一个证据是， 不同版本的GRFT蛋白的临床试验现已成功 其中一项已完成，其结果已公布。我们继续这些合作， 帮助通过诊所推进基于GRFT的产品。最后，两个额外的I期临床 用于抗SARS-CoV-2的QGRFT突变蛋白的鼻用制剂的试验已经 启动。

Our efforts have led to the discovery of several classes of bioactive proteins as well as publications on their potential activity. This research has also led to 34 patents overall and significant interest for our discoveries from different licensees. Recent papers of particular interest include our report of fast-dissolving formulations of the protein griffithsin (GRFT) which showed in vivo activity against SHIV, HSV-2 and HPV,18 the expression of GRFT in rice with two other microbicide candidates17 which led to a new patent filing and the discovery of a new class of cyclic peptides called Tyr-lock peptides which also led to a new patent. Additional evidence for the success of PCMBS Project 2 is the fact that two Phase I clinical trials of different versions of the protein GRFT have now been successfully completed one of which whose results have been published. We continue these collaborations to help advance GRFT-based products through the clinic. Finally, two additional Phase I clinical trials of nasal formulations of the QGRFT mutant protein for use against SARS-CoV-2 have been initiated.